AHF (acute heart failure) causes significant morbidity and mortality. Recent studies have postulated that the expression of inflammatory mediators, such as cytokines and chemokines, plays an important role in the development and progression of heart failure. A pro-inflammatory state has been postulated as a key factor in triggering CMV (cytomegalovirus) reactivation. Therefore we sought to determine the prevalence of active CMV infection in immunocompetent patients admitted for AHF and to quantify the association with the risk of the combined end point of death or AHF readmission. A total of 132 consecutive patients admitted for AHF were enrolled in the present study. Plasma CMV DNAaemia was assessed by qRT-PCR (quantitative real-time PCR), and cytokine measurements in plasma were performed by ELISA. Clinical data were evaluated by personnel blinded to CMV results. The independent association between active CMV infection and the end point was determined by Cox regression analysis. During a median follow-up of 120 [IQR (interquartile range), 60-240] days, 23 (17.4 %) deaths, 34 (24.2 %) readmissions for AHF and 45 (34.1 %) deaths/readmissions for AHF were identified. Plasma CMV DNAaemia occurred in 11 (8.3 %) patients, albeit at a low level (<100 copies/ml). The cumulative rate of the composite end point was higher in patients with CMV DNAaemia (81.8 compared with 29.8 %; P < 0.001). After adjusting for established risk factors, the occurrence of CMV DNAaemia was strongly associated with the clinical end point [hazard ratio = 4.39 (95 % confidence interval, 2.02-9.52); P < 0.001].
INTRODUCTION
Despite recent therapeutic innovations, advanced HF (heart failure) remains a serious medical condition with morbidity and mortality rates comparable or even higher than that for most malignancies [1] . Several studies support the involvement of inflammatory pathways in triggering the initiation and favouring the progression of HF [2] [3] [4] . In this context, pro-inflammatory cytokines, such as TNF-α (tumour necrosis factor-α) and IL (interleukin)-6, appear to have detrimental effects on cardiac function [2] [3] [4] . Nevertheless, the prognostic implication of the inflammatory responses in HF remains unclear. The role of hyperinflammatory states in promoting CMV (cytomegalovirus) reactivation has been highlighted previously [5] . CMV infection causes significant morbidity and mortality in immunocompromised patients not only as a result of virus cytopathogenicity ('direct effects'), but also by virtue of its immunomodulatory properties ('indirect effects') [6] . The latter effects may account for the reported association between CMV infection and chronic allograft rejection in solid organ transplant recipients, particularly transplantrelated vasculopathy, whose histopathology remarkably resembles that of atherosclerosis [7] . In line with this, a role for CMV in the pathogenesis of cardiovascular diseases has been postulated [7, 8] .
Results obtained in the murine CMV model indicate that a pro-inflammatory state is a critical factor in promoting CMV reactivation [5] . In this mechanistic model, TNF-α, a cytokine known to directly stimulate immediate early CMV gene expression in vitro [9] , may play a pivotal role [10] . In fact, intraperitoneal administration of well-known inflammatory mediators in HF, such as LPS (lipopolysaccharide) and TNF-α, were capable of reactivating CMV from latency in lungs of previously healthy mice [5] . We thus hypothesized that active CMV infection was likely to occur in patients with AHF (acute HF) and that it may have prognostic implications. In the present study, we sought to determine in a cohort of patients with AHF: (i) the prevalence of CMV infection; (ii) whether active CMV infection was associated with an increased risk for the composite end point of short-term all-cause mortality or readmission for AHF and; (iii) whether those patients with an active CMV infection had higher rates of hospitalized-day/weeks of follow-up.
MATERIALS AND METHODS

Study group
We prospectively studied a cohort of 138 patients consecutively admitted to the Cardiology Department of Hospital Clínico Universitario de Valencia from 1 November 2008 to 19 May 2009 with the diagnosis of AHF. Diagnosis of AHF was defined as the rapid onset of symptoms and signs secondary to abnormal cardiac function and the presence of objective evidence of structural or functional abnormality of the heart at rest (cardiomegaly, third heart sound, cardiac murmur, abnormality in the echocardiogram or raised natriuretic peptide levels), following current guidelines [11] and established by a trained cardiologist. Exclusion criteria were known or suspected infections, any systemic inflammatory disease different from HF, immunodeficiency, end-stage renal disease undergoing dialysis, cancer, blood transfusion within 30 days, and the need for mechanical ventilation before blood sampling. At total of 138 patients were initially selected, but six patients were later excluded because of death before blood sampling (n = 2), a final diagnosis of acute coronary syndrome (n = 2), pneumonia (n = 1) and cancer (n = 1), leaving the study sample to be 132 patients. Demographic information, medical history, vital signs, 12-lead ECG, laboratory data and drug utilization were routinely determined in the Emergency Department and throughout the hospital course following preestablished registry questionnaires. LVEF (left ventricular ejection fraction) was assessed using two-dimensional echocardiography (Agilent Sonos 5500-Phillips) in all patients during index hospitalization.
All patients received intravenous treatment with furosemide at least during the first 48 h of admission. Treatment with ACEIs (angiotensin-converting enzyme inhibitors), ARBs (angiotensin receptor blockers), β-blockers, an aldosterone antagonist, anticoagulants and other therapeutic strategies was individualized following established guidelines [11] .
Patients' follow-up was censored if death occurred or if having undergone cardiac transplantation or cardiac valve replacement surgery. The composite of all-cause mortality and readmission for AHF was selected as the main clinical end point. As secondary end point, the cumulative incidence rate of days hospitalized/week of follow-up was compared between those with and without CMV DNAaemia.
The study was approved by an institutional review committee and patients gave written informed consent.
CMV assays
Following an overnight fast, venous blood samples were drawn from the antecubital vein between 08:30 and 09:30 hours with patients resting in the supine position for at least 15 min prior to sampling. IgG and IgM antibodies against CMV were detected by means of a commercial immunoassay (Architect CMV IgG assay; Abbott Diagnostics). CMV DNA load was measured by qRT-PCR (quantitiative real-time PCR) with the Abbott CMV PCR kit (produced by Qiagen for Abbott Diagnostics), performed using the m2000RT system (Abbott Molecular) and following the manufacturer's instructions, as described previously [12] . DNA extractions (from 500 μl of plasma) were performed using the Abbott mSample preparation system DNA kit on the m2000 SP instrument (Abbott Molecular). The reported limit of detection of the assay [95 % CI (confidence interval)] is 25 CMV DNA copies/ml [12] . The assay is, however, able to reliably quantify lower CMV DNA loads (D. Navarro, unpublished work). Specimens with CMV DNA loads <25 copies/ml were re-assayed using a different aliquot and were regarded as positive if they yielded a reproducible CMV DNA load value. Measurements were performed by a technician blinded to patient diagnosis and evolution.
Plasma cytokines analysis
Plasma levels of TNF-α, IL-6, IL-1β and IL-10 were quantified by ELISA using commercially available kits (human IL-1β, IL-6, TNF-α and IL-10 ELISA Ready-SET-Go!; eBioscience). The sensitivity claimed by the manufacturer for the different cytokine assays was: 3.0 pg/ml for TNF-α, 4.0 pg/ml for IL-1β, 2 pg/ml for IL-6, and 2.0 pg/ml for IL-10. High-sensitivity ELISAs were used for cytokine measurements in samples giving values below the detection limit in the respective low-sensitivity assay. The concordance between the values obtained in the low-sensitive assay (for those above the detection limit) and those in the high-sensitive assay approached 100 %.
Statistical analysis
Continuous variables are expressed as medians [IQR (interquartile range)]. Discrete variables are presented as numbers (percentages). Baseline characteristics were compared among those patients with and without CMV DNAaemia. Using the standard cut-off points, CMV DNAaemia was categorized by the presence of >25 copies/ml, 25 copies/ml or negative (undetectable CMV DNA) results. The composite of mortality/AHF rehospitalization rates was depicted among the CMV DNAaemia status using the Kaplan-Meier method, and their differences were tested using the Peto-Peto Prentice test. The independent association between CMV DNAaemia categories and the main outcome was assessed with Cox regression analysis. Candidate covariates for the initial multivariable model included all variables listed in Table 1 , including cytokines. Then, a reduced and parsimonious model was derived by using the Royston and Altman model-selection algorithm [13] . The final Cox model included the following covariates: previous admission for AHF, SBP (systolic blood pressure) at admission (in mmHg), Charlson co-morbidity index, serum sodium (mmol/l), serum NT-proBNP (N-terminal pro-brain natriuretic peptide) (pg/ml) and serum CA125 (carbohydrate antigen 125). The proportionality assumption for the hazard function over time was tested by means of the Schoenfeld residuals. The model's discriminative ability was assessed using the Harrell's C-statistic while its calibration was tested using the Gronnesby and Borgan test [14] . For the secondary analysis, negative binomial regression was used to determine the IRR (incidence rate ratio) of patient's days hospitalized/week of follow-up according to CMV DNAaemia status. Independent predictors included in this model were: age, smoking status, last NYHA (New York Heart Association) class measured under stable conditions, previous admission for AHF, valvular heart disease, anaemia, lymphocyte relative count, CA125, uric acid, TNF-α, LVEF, and treatment with furosemide, espironolactone, statins and inotropic drug support.
A two-sided P value of <0.05 was considered to be statistically significant for all analyses. All analyses were performed using STATA 11 (StataCorp).
RESULTS
Prevalence of active CMV infection
A total of 129 patients (97.7 %) were CMV IgGseropositive. A single analysis for the presence of CMV DNA in plasma was performed [median (IQR) of 3 (1-5) days following admission]. CMV DNA was detected in plasma from 11 (8.3 %) patients, four of whom had CMV DNAaemia levels of >25 copies/ml [median (IQR), 43 (31-72) copies/ml]. Lower CMV DNAaemia levels [median (IQR), 10 (6-12) copiesl/ml] were consistently detected in the remaining seven patients. Six patients (4.6 %) tested positive for CMV IgMs, two of whom tested positive for CMV DNAaemia. Time to sampling after admission did not differ significantly (P = 0.656) between patients with or without CMV DNAaemia.
Characteristics of patients across CMV status
The mean age of patients in the sample was 76 + − 13 years; 64 patients (48.5 %) were female, 70 (53 %) had been admitted previously for AHF and 78 (59.1 %) exhibited an LVEF 45 %. Table 1 shows the clinical characteristics of the study population according to the CMV DNAaemia status. Patients with active CMV infection more frequently had an LVEF <45 %, lower median SBP and DBP (diastolic blood pressure), and a trend towards a higher median serum NTproBNP levels. Interestingly, no differences were found in age, gender, cardiovascular risk factors, aetiology, presentation, co-morbidity and treatment between the groups.
Inflammatory status and active CMV infection
Plasma levels of several pro-inflammatory and immunoregulatory cytokines were measured in patients with (at the time of CMV DNA detection) and without active CMV infection. Patients exhibiting CMV DNAaemia had lower median IL-10 values and higher median TNF-α/IL-10 and TNF-α/IL-6 ratios (Table 1 ). These differences were particularly evident when patients were stratified on the basis of their CMV DNAaemia patients who exhibited CMV DNAaemia are shown in Table 2 . Using a multivariate analysis, after adjusting for established prognostic factors and potential confounders, including previous admission for AHF, SBP, Charlson In addition, a risk gradient was found according to the magnitude of the viral load. Thus, compared with patients with undetectable CMV DNAaemia, patients with >25 copies/ml had a prohibitive adjusted increased risk of death or readmission [HR, 13.6 (95 % CI, 3.98-46.58); P < 0.001], whereas patients with CMV DNAaemia of 25 copies/ml had an intermediate increased risk [HR, 2.93 (95%CI, 1.11-7.71); P < 0.030] ( Table 3) . It is noteworthy to point out that all patients who displayed CMV DNAaemia of >25 copies/ml died within the first 100 days following index admission (one of them died during index admission and in the rest death was preceded by a readmission for AHF) ( Table 2) .
CMV infection and death/readmission for AHF
Likewise, patients with detectable CMV-specific IgMs had an increased risk of the composite end point (Figure 3 ). This excess of risk attributable to the presence of CMV-specific IgMs remained strongly significant in multivariate analysis, including CMV DNAaemia as a variable [HR, 6.91 (95 % CI, 1.95-24.5); P = 0.003]. As the presence of DNAaemia and CMV-specific IgMs yielded similar prognostic and biological importance, combining them into one category led us to identify a subgroup of subjects (n = 15) with a very high risk of death/rehospitalization for AHF [HR, 4.70 (95 % CI, 2.29-9.61); P < 0.001].
Harrell's C-statistics of the multivariate models that included CMV DNAaemia either as a binary or threelevel variable showed higher discriminative ability (0.787 and 0.789) than the model without it (0.764). The Gronnesby and Borgan test of goodness-of-fit showed a good model calibration (P = 0.579).
CMV and cumulative incidence of hospitalized-day rates
The presence of CMV DNAaemia identified a subset of patients with a higher median (IQR) length of stay during the index hospitalization [23 (11) 
DISCUSSION
To the best of our knowledge, the present study is the first to report that not only active CMV infection occurs in patients with AHF, but also it appears to exert a detrimental effect on prognosis.
It is now widely accepted that activation of the immune system occurs in patients with chronic HF, leading to an inflammatory state that appears to be a determinant in disease progression [2] [3] [4] 15] . In this sense, serum levels of TNF-α, IL-6 and soluble TNFreceptors I and II have been shown to correlate with disease stage and progression, and ultimately with a poorer prognosis in chronic HF and AHF [2] [3] [4] 16, 17] . TNF-α has been shown to trigger CMV reactivation from latency at the cellular level [5] . In this context, active CMV infection has been shown to occur frequently in critically ill patients without canonical immunosuppression [18] [19] [20] , especially in those with severe sepsis, a biological condition leading to CMV reactivation in a murine CMV model [5] . In this setting, CMV may perpetuate and aggravate the inflammatory state by virtue of its immunomodulatory properties [21, 22] . This may account for the reported association between CMV infection and prolonged hospitalization, longer duration of mechanical ventilation, and higher rates of nosocomial infections and overall mortality in this clinical setting [18] [19] [20] .
On the basis of the above assumptions, we reasoned that active CMV infection was likely to occur in patients with HF, especially during an acute episode. Indeed, we found that CMV DNAaemia occurred at a low level (<100 copies/ml) in 8.7 % of cases. The above findings are reminiscent of those reported in critically ill patients without canonical immunosuppression experiencing an active CMV infection, in which a rapid expansion of CMV-specific functional T-cells in response to CMV replication keeps systemic CMV load at a low level until complete resolution of the episode [23] . In addition, in our present cohort, the occurrence of CMV DNAaemia was independently associated with an increased risk of morbidity and mortality. This association was particularly evident when patients were stratified according to their level of CMV DNAaemia, with those displaying CMV DNAaemia levels >25 copies/ml being at the highest risk. In fact, the four patients in the upper CMV DNAaemia category died during the first 100 days following the index admission. In line with our findings, the magnitude of the CMV DNA load has recently been reported to be independently and quantitatively associated with prolonged hospitalization and death after adjusting for parameters indicative of severity, such as APACHE II (Acute Physiology and Chronic Health Evaluation II) score and other potential confounders, in a cohort of critically ill patients attending different intensive care units [19] .
Furthermore, the presence of CMV-specific IgMs, a well-known marker of CMV reactivation in immunocompetent individuals harbouring latent CMV [24] , was independently associated with an increased risk of death/readmission for AHF. The possibility exists nevertheless that IgMs detected were not truly CMVspecific [24] .
Whether CMV is a direct cause of morbidity and mortality in patients with AHF or is simply a surrogate marker for disease severity could not be elucidated in the present study. CMV may be reactivated in patients with AHF in the setting of a pro-inflammatory state. As an immunomodulatory agent, CMV may enhance inflammation which would result in further myocardial injury [4, 15, [25] [26] [27] or may even increase the risk of secondary infections [22] , a well recognized precipitating factor for HF descompensation [11] . The fact that patients with active CMV infection exhibited an enhanced immunoinflammatory state (higher plasma TNFα-/IL-10 and IL-6/IL-10 ratios) when compared with those without active infection provides support to the plausibility of this hypothesis.
Our results, however, must be interpreted with caution. First, this is a preliminary observational study that includes a limited number of patients with AHF. Secondly, despite the strength of the association, the low number of patients with active CMV infection precludes the inference of more precise confidence intervals. Thirdly, as no sequential measurements were performed, peak CMV DNAaemia values for some patients may have been missed. Finally, some patients might have been miscategorized due to the intrinsic interassay coefficient of variation of the qRT-PCR used in the present study (estimated to be within 20-30 % for low CMV DNA loads).
Conclusions
The present preliminary study indicates that active CMV infection may occur in immunocompetent patients admitted for AHF, albeit at a low frequency, and that the presence of CMV DNAaemia was independently associated with a higher risk of the composite end point of death/readmission for AHF. Further studies are warranted in order to: (i) confirm the presence of active CMV infection in AHF, and (ii) determine whether active CMV infection plays a direct role in the progression of the disease or if it is merely an epiphenomenon linked to the severity of the inflammatory state. Should the results of the present study be confirmed, then patients displaying CMV DNAaemia may constitute a subgroup of patients with AHF amenable to be managed aggressively or with specific therapeutic modalities, such as immunomodulation, anti-inflammatory therapies or even antiviral agents.
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